Today in Peak History (June 21-30)
Release time:
2020-08-14
Today in Peak History (6# March 21 - 30 )
◆ 1993 6 29 , the "93 Peak Cup" Celebrity Bridge Invitational Tournament jointly organized by Jianfeng Group, China Bridge Association and New Sports Magazine was held in the Great Hall of the People in Beijing. Wan Li, former chairman of the National People's Congress, Ngapoi Ngawang Jigme, former vice chairman of the National People's Congress, Wang Hanbin and other state leaders, and more than 20 150 people from various ministries and commissions, the press, and sports circles participated in the competition. On the same day, leaders such as Wan Li and Wang Hanbin met with Du Zihong, chairman and general manager of the group company, respectively in the Great Hall of the people.
1996 6 September 28 , Jianfeng Group merged Linhai Pharmaceutical Factory across regions, which opened the prelude to entering the pharmaceutical industry. On the same day, Taizhou Jianfeng Cement Company announced its establishment. This is the first time that the Jianfeng Cement business has made a cross-regional investment out of the Jinqu Basin.
1996 6 September 30 , the load linkage test run of the rotary kiln production line of Jinguo Cement Company (later Jinma Cement Company) was successful, and Peak Cement officially entered the "rotary kiln era".
2007 6 September 28 , Fuyang Jianfeng Cement Company held a commencement ceremony for the waste heat power generation project, which was the first cement waste heat power station in Jianfeng. In the cement projects invested after the peak, energy-saving and consumption-reducing facilities such as waste heat power generation have become "standard".
2014 6 September 23 , the two products of Spike Pharmaceutical Milk Thistle Extract and Ginkgo Leaf Extract passed the certification of Korea GMP , thus Spike Pharmaceutical became the Chinese traditional medicine extract manufacturer certified by Korea GMP .
2014 6 May 27 , daye peak cement company obtained the first batch of low-carbon product certification certificates.
2016 6 May 27 , the first doctor of Jianfeng Pharmaceutical Postdoctoral Workstation entered the station to open the topic. (Xu Xia finishing)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page